Mazou Ngou Temgoua on SCAF: Subclinical Atrial Fibrillation on Treatment with Apixaban or Aspirin
Mazou Ngou Temgoua, Contract hospital practitioner at Châteauroux-Le Blanc Hospital Center, shared on LinkedIn:
”Major Bleeding With Apixaban vs Aspirin
A Subanalysis of the ARTESiA Randomized Clinical Trial
Question In patients with subclinical atrial fibrillation (SCAF) treated with apixaban or aspirin, what are the sites, severity, and factors associated with major bleeding?
Findings In this subanalysis of the Apixaban for the Reduction of Thromboembolism in Patients With Device-Detected Subclinical Atrial Fibrillation (ARTESiA) randomized clinical trial including 3961 patients, although the rate of major gastrointestinal bleeding was higher with apixaban compared with aspirin, critical site, intracranial bleeding, and fatal bleeding were similar between arms.
Most major bleeding events in both groups were characterized by decreased hemoglobin and were not emergencies.
Meaning This study found that in patients with SCAF, apixaban increased major gastrointestinal bleeding compared with aspirin but intracranial and fatal bleeding events were similar between groups; most bleeding events were nonemergencies characterized by a decrease in hemoglobin.
Major Bleeding With Apixaban vs Aspirin: A Subanalysis of the ARTESiA Randomized Clinical Trial | Bleeding and Transfusion | JAMA Cardiology | JAMA Network”
Read the full article here.
Article: Major Bleeding With Apixaban vs Aspirin: A Subanalysis of the ARTESiA Randomized Clinical Trial
Authors: Deborah M. Siegal, Christian Sticherling, Jeff S. Healey, William F. McIntyre, Lene S. Christensen, Ratika Parkash, Thomas Vanassche, David Conen, Michael Gold, Christopher B. Granger, Jens Cosedis Nielsen, Marc Carrier, Daniel M. Wojdyla, Julia W. Erath, Lena Rivard, Valentina Kutyifa, David J. Wright, Renato D. Lopes
Stay updated on all scientific advances with Hemostasis Today.
-
Feb 13, 2026, 06:01Heghine Khachatryan: Privileged To Participate In the ASH MMENA Partner Societies Leadership Meeting
-
Feb 12, 2026, 16:36Tagreed Alkaltham: Tranexamic Acid in PBM
-
Feb 12, 2026, 16:35Paul Lambis Announces Maria Hadjidemetriou as a Speaker at Cyprus Diaspora Forum
-
Feb 12, 2026, 16:34Rahul Bhargava: Breaking Myths About Bone Marrow Transplant
-
Feb 12, 2026, 16:29Arun V J: Can You Be A Doctor And Still Be Stupid?
-
Feb 12, 2026, 16:26Changing the Narrative Around PPH – End Postpartum Hemorrhage
-
Feb 12, 2026, 16:20Mahesan Subramaniam: The Protective Switch in Brain Immune Cells Could Slow Alzheimer’s Disease
-
Feb 12, 2026, 16:13Lale Tokgözoğlu: Top 10 Dyslipidemia Papers of 2025
-
Feb 12, 2026, 16:10Neelam Mohan: Breaking Down Anemia from Causes and Testing to Treatment and Prevention